Biomarker Assay Validation

Biomarker Assay Validation designates the systematic experimental process demonstrating that a biomarker measurement method reliably, reproducibly, and accurately quantifies the intended analyte in the relevant biological matrix and patient population, following established regulatory guidelines ensuring data quality sufficient for intended regulatory or clinical decision-making uses.

The biopharmaceutical industry validates biomarker assays according to regulatory fit-for-purpose principles calibrating validation stringency to intended use. Exploratory biomarkers supporting mechanistic understanding require less rigorous validation than biomarkers supporting regulatory decisions. Validation experiments assess accuracy, precision, selectivity, sensitivity, dilutional linearity, and stability in relevant sample matrices. Immunoassays require additional validation addressing specificity of antibody reagents and potential interference from anti-drug antibodies. Genomic and transcriptomic biomarker assays require platform-specific validation addressing amplification efficiency, specificity, and normalisation. Regulatory submissions include biomarker assay validation documentation demonstrating data quality. As biomarker-guided development expands and regulatory acceptance of biomarker endpoints grows, robust assay validation continues ensuring measurement quality supports sound decisions.